Neonatal Drug Therapy Manual

Lipid Emulsions 20% (SMOFlipid)

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Updated April 22, 2021 - 8:14am

Alternate Name(s): 
SMOFlipid
Classification: 
Lipid injectable emulsion comprised of 30% soybean oil, 30% medium chain triglycerides, 25% olive oil and 15% fish oil
Original Date: 
March 2021
Indications: 
  • Source of calories and essential fatty acids and omega-3 fatty acids to patients needing parenteral nutrition therapy
Administration: 
  • IV continuous infusion through a peripheral or central catheter
Dosage: 
  • Initiate a 1 g/kg/day and advance daily by 0.5 - 1 g/kg/day to target dose of 3 g/kg/day 
  • Lower dosage is recommended with hyperbilirubinemia and severe liver insufficiency.
Side Effects: 
  • Endocrine and metabolic : blood triglycerides increased 
  • Hepatic: cholestasis, hyperbilirubinemia, abnormal hepatic function tests 
Parameters to Monitor: 
  •  Triglycerides (daily while increasing dose then weekly once stable)
  •  Liver functions tests 
  •  Coagulation parameters (monthly)
Reconstitution and Stability: 
  • Syringe hang time: 24 hours
  • Tubing change time: 24 hours
Compatibility: 

The co-infusion of drugs and parenteral nutrition should be avoided.  If a separate site is not available, the drug may be given through a separate line that has a Y-connection to the parenteral nutrition as close to the patient as possible.

- Y-site Compatible: acetaminophen, ampicillin, cefotaxime, dexmedetomidine, dobutamine, dopamine, epinephrine, fentanyl, furosemide, heparin, hydromorphone, insulin, ketamine, meropenem, metronidazole, midazolam, morphine, norepinephrine, penicillin, piperacillin/tazobactam, vancomycin, zidovudine

 

Incompatible: acyclovir, amiodarone, ceftazidime, ceftriaxone, ciprofloxacin, famotidine, fluconazole, gentamicin, hydrocortisone, milrinone, pantoprazole, rocuronium, sodium bicarbonate, tobramycin

Notes: 
  • 20% lipid = 2 Kcal/mL
References: 

-  Emma L Ross, PharmD, BCPPS, Allison Salinas, PharmD, Kirsten Petty, PharmD, Cheng Her, PhD, John F Carpenter, PhD, Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing, American Journal of Health-System Pharmacy, Volume 77, Issue 23, 1 December 2020, Pages 1980–1985, https://doi.org/10.1093/ajhp/zxaa299

 

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.